Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?The Motley Fool • 12/11/23
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per personBusiness Insider • 12/09/23
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is NonplussedSeeking Alpha • 12/09/23
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in USInvestopedia • 12/08/23
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell DiseaseBusiness Wire • 12/08/23
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatmentMarket Watch • 12/08/23
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing TreatmentInvestors Business Daily • 12/08/23
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?The Motley Fool • 12/08/23
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patientsCNBC • 12/07/23
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/06/23
Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 27.15%: Read This Before Placing a BetZacks Investment Research • 12/06/23
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune DiseaseGlobeNewsWire • 12/04/23